CompletedPhase 3NCT00005589
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
Studying Follicular lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- EBMT Solid Tumors Working Party
- Principal Investigator
- Ruth Pettengell, MDSt George's, University of London
- Intervention
- filgrastim(biological)
- Enrollment
- 460 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 1999 – 2013
Study locations (30)
- Sydney Cancer Centre at Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
- Westmead Institute for Cancer Research at Westmead Hospital, Westmead, New South Wales, Australia
- Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
- Royal Adelaide Hospital Cancer Centre, Adelaide, South Australia, Australia
- Queen Elizabeth Hospital, Woodville, South Australia, Australia
- Royal Melbourne Hospital, Parkville, Victoria, Australia
- Fremantle Hospital, Fremantle, Western Australia, Australia
- Royal Perth Hospital, Perth, Western Australia, Australia
- Allgemeines Krankenhaus - Universitatskliniken, Vienna, Austria
- Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium
- Institut Jules Bordet, Brussels, Belgium
- Academisch Ziekenhuis der Vrije Universiteit Brussel, Brussels, Belgium
- Universitair Ziekenhuis Gent, Ghent, Belgium
- U.Z. Gasthuisberg, Leuven, Belgium
- CHU Liege - Domaine Universitaire du Sart Tilman, Liège, Belgium
- +15 more locations on ClinicalTrials.gov
Collaborators
Lymphoma Trials Office
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00005589 on ClinicalTrials.govOther trials for Follicular lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07128641Odronextamab in Low Tumor Volume Advanced FLGottfried von Keudell, MD PhD
- RECRUITINGNANCT07126678Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular LymphomaThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGEARLY PHASE1NCT06976437A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant TumorsYANRU WANG
- RECRUITINGNCT06794268A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing SettingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
- RECRUITINGPHASE1NCT07093073Clinical Study of U01（ssCART-19） in Patients With B-Cell LymphomaShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- RECRUITINGPHASE2NCT06959732Zanubrutinib Combined With G-CVP in Previously Untreated FLCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGEARLY PHASE1NCT06662227Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell TumorsWondercel Biotech (ShenZhen)
- RECRUITINGPHASE3NCT06549595A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsAstraZeneca